Lamy Lexel advised SAJES Patrimoine on its sale of Stève Consultants, adviser in healthcare products, medical device research and market strategy, to Cytel. This transaction demonstrates Lamy Lexel’s expertise in mergers & acquisitions and the healthcare industry.
Cytel is a global software developer specialising in clinical trial design and healthcare analytics. The acquisition of Stève Consultants bolsters Cytel’s capabilities in market access, health economics and outcomes research, and real-world evidence.
Since its inception in 2006, Stève Consultants has helped clients maximise market access by advising in medical device pricing and reimbursement strategies, data synthesis and theraputic technology in oncology, immunology, and rare and infectious diseases.
Lamy Lexel is thrilled for Stève Consultants in its successful sale and is grateful for the opportunity to deepen the firm’s collective knowledge and experience in share sale and purchase agreements, particularly the:
- Organisation and execution of the sale carried out by the Corporate, Mergers & Acquisitions, Tax, and Labour and Employment groups
- Drafting and finalisation of legal documents by the Corporate group
Lamy Lexel wishes Stève Consultants and Cytel a successful future together !